biostudies-literatureFrey SEHHSNCATS NIH HHSNIAID NIH HHS126702https://www.ebi.ac.uk/biostudies/studies/S-EPMC12096342biostudies-literatureUnknown47<h4>Introduction</h4>While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.<h4>Methods</h4>A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4).<h4>Results</h4>The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated. Little antibody activity was detected against the A(H7N9) vaccine antigen afVaccineSafety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.PMC12096342UL1 TR002243HHSN272201300019CUM1 AI148685HHSN27220139921IHHSN272201300023IHHSN27200015HHSN272201300021I75N93021C00012HHSN272201300016CHHSN272201300015CHHSN272201300019IHHSN272201300023CHHSN272201300016IHHSN272201300015IAtmar RLAbate GPaulsen GRupp RGoepfert PCreech CBWeiss JFrey SEBrady RWegel ARoberts PCEl Sahly HMJackson LfalseSafety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®.<h4>Introduction</h4>While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.<h4>Methods</h4>A Phase II study was conducted in healthy adults aged 18-64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1-3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4).<h4>Results</h4>The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated. Little antibody activity was detected against the A(H7N9) vaccine antigen af2025-01-01T00:00:00Z2025 Feb2026-07-15T21:33:19.045Z2026-07-09T10:14:46.613ZS-EPMC120963423979843410.1016/j.vaccine.2024.126702